{"id":"64686abedb85","type":"article","url":"https://hartvaat.nl/2024/06/01/glycemische-variabiliteit-en-mortaliteit-bij-hartfalen-meta-analyse/","title":"Glycemische variabiliteit en mortaliteit bij hartfalen: meta-analyse","title_en":"A meta-analysis of the relationship between glycaemic variability and the mortality of patients with heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["acuut-hartfalen"],"journal":"ESC heart failure","doi":"10.1002/ehf2.14627","source_url":"https://doi.org/10.1002/ehf2.14627","authors":["Xiaoxiao Fu","Yang Wei","Jun Fang"],"significance":5,"published":"2024-06-01","source_date":"2024-06-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This meta-analysis found that greater glycaemic variability is associated with increased mortality in patients with heart failure. The findings suggest that stable glucose control may be prognostically more favourable than aggressive glucose lowering accompanied by fluctuations.","created":"2026-07-03T10:30:57Z","updated":"2026-07-03T18:39:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse toonde dat hogere glycemische variabiliteit geassocieerd is met verhoogde mortaliteit bij hartfalenpatiënten. Stabiele glucosecontrole is prognostisch gunstiger dan agressieve verlaging met schommelingen.","abstract_original":"Recent findings indicate that fluctuations in blood glucose could potentially increase the risk of unfavourable outcomes in individuals with cardiovascular conditions. The objective of the research was to assess the correlation between glycaemic variability (GV) and the mortality of patients with heart failure (HF) through a comprehensive review and meta-analysis. Longitudinal follow-up studies comparing the mortality risk between HF patients with higher and lower GV were identified by searching Medline, Embase, Web of Science, and Cochrane Library databases. The results were combined using a random-effects model that accounted for the potential variability. The meta-analysis included nine cohort studies involving 76 843 patients diagnosed with HF, out of which 35 853 patients died within a follow-up period of up to 86 months. The combined findings indicated that a significant increase in GV was linked to an elevated risk of mortality in patients with HF during the follow-up period (RR 2.18, 95% CI 1.61 to 2.96, P < 0.001, I2 = 83%). The relationship between GV and mortality in HF patients was not significantly influenced by the patients' diabetic status (diabetic or non-diabetic), type of GV (acute or long-term GV), study design (prospective or retrospective), country of the study (Asian or non-Asian), follow-up durations, or the scores of study quality (P-values for subgroup differences all >0.05). A high GV could be a risk factor of mortality of patients with HF."}